Business Wire

NY-ROCKEFELLER-ASSET

4.2.2021 09:02:09 CET | Business Wire | Press release

Share
Rockefeller Asset Management Launches Rockefeller Climate Solutions UCITS Driven by Nordic Region Institutional and Professional Investors

On December 9, 2020, Rockefeller Asset Management (RAM), a division of Rockefeller Capital Management, launched its third equity UCITS fund, the Rockefeller Climate Solutions Fund. This expands the firm's spectrum of sustainable investment solutions, including US and Global ESG equity strategies, all available to the European market through the Rockefeller Capital Management UCITS ICAV platform.

RAM, in collaboration with The Ocean Foundation (TOF), established the Climate Solutions Strategy nearly nine years ago based on the belief that climate change will transform economies and markets through changing regulation, shifting buying preferences from next-generation consumers, and technological advancements. This global strategy deploys a high conviction, bottom-up approach to investing in companies with meaningful revenue exposure to key environmental sectors such as renewable energy, energy efficiency, water, waste management, pollution control, food & sustainable agriculture, healthcare mitigation, and climate support services. The portfolio managers believe that companies producing climate mitigation and adaptation solutions will outperform broader equity markets over the long-term. The Climate Solutions Strategy, which is only now being broadly marketed to outside investors, outperformed the MSCI ACWI Index by 18.59% (on a net basis) in 2020 and 4.27% annualized over the past 5-years.

Rockefeller Climate Solutions UCITS is co-managed by Casey Clark, CFA, and Rolando Morillo, who lead RAM's thematic equity strategies, leveraging the intellectual capital built from RAM's four decades of ESG investing experience. Since the inception of the Climate Solutions Strategy, RAM has also benefited from the environmental and scientific expertise of The Ocean Foundation (TOF), a non-profit dedicated to conserving ocean environments around the world. Mark J. Spalding, the President of TOF, and his team serve as advisors and research collaborators to help bridge the gap between science and investing and contribute to the strategies, idea generation, research, and engagement process.

Rolando Morillo, Fund Portfolio Manager, says: "Climate change is becoming a defining issue of our time. We believe investors can generate alpha and positive outcomes by investing in companies producing climate mitigation or adaption solutions with distinct competitive advantages, clear growth catalysts, strong management teams, and attractive earnings potential."

Nearly a decade ago, a group of forward-thinking investors asked Rockefeller to build a portfolio that has the potential to generate excess returns and help solve the climate crisis. In response to their interest, we built the Rockefeller Climate Solutions Strategy and are excited to open it to an expanded audience with the launch of our UCITS fund," said Chip Montgomery, Head of Business Development and Corporate Strategy. "We are seeing growing demand in Europe for thematic investing, driven by concern about climate change, especially in the Nordic Region, which has been at the forefront of sustainable investing. Gjensidigestiftelsen, the largest Norwegian financial foundation, is a cornerstone investor in the fund. We are proud that the fund could play a small part in the great work that Gjensidigestiftelsen is doing to promote health and safety initiatives."

Rockefeller Climate Solutions UCITS is available to institutional and retail investors in certain European markets, featuring a founders' share class with favorable economics and terms for select early-stage investors, and is available for passporting into many European countries.

RAM leverages the relationships of Hyde Park Investment Ltd for Europe and Archipelago Partners in the Nordic region for targeted capital raising.

About Rockefeller Asset Management (RAM)

Rockefeller Asset Management, a division of Rockefeller Capital Management, offers global, U.S., non-U.S., and environmental, social and governance ("ESG") equity strategies, as well as a range of tax-exempt and taxable fixed income strategies, serving institutions, high net-worth individuals and families. With over 30 years of experience in global investing, we pair our distinctive worldview and long-term investment horizon with thorough fundamental research combining traditional and non-traditional analysis. We offer strategies that seek to outperform benchmarks over multiple market cycles, driven by a disciplined investment process in a highly collaborative team culture. As of December 31, 2020, Rockefeller Asset Management had $11.2B in assets under management. For more information visit https://rcm.rockco.com/ram .

About The Ocean Foundation

The Ocean Foundation (TOF) is an international community foundation based in Washington D.C., established in 2003. As the only community foundation for the ocean, its mission is to support, strengthen, and promote organizations dedicated to reversing the trend of destruction of ocean environments around the world. This model enables the foundation to serve donors (expert management of a portfolio of grants and grantmaking), generate new ideas (develop and share content on emerging threats, potential solutions, or better strategies for implementation), and nurture implementors (help them be as effective as they can be). The Ocean Foundation and its current staff have been working on ocean and climate change issues since 1990; on Ocean Acidification since 2003; and on related "blue carbon" issues since 2007. For more information visit https://oceanfdn.org/ .

About Gjensidigestiftelsen

A modern financial foundation supporting a philanthropic mission with a 200 year history from the insurance industry. Gjensidigestiftelsen is the largest Norwegian financial foundation – established in 2007 as a charitable foundation then converted into a financial foundation prior to the listing of Gjensidige Forsikring ASA in 2010.

The proceeds from the sale of 38 percent stake have been invested in a diversified portfolio managed by Gjensidigestiftelsen's professional in-house investment team. The financial return earned is fully dedicated to the advancement of the Foundation's program and philanthropic purposes. The Gjensidige Foundation's financial objectives are to manage its long-term ownership of Gjensidige, to pass on a share dividend to Gjensidige's non-life insurance customers, and to manage the revenue raised from the sale of shares.

Our mission is to promote good lives in a safe society. The Gjensidige Foundation provides funding and support to charitable organizations working within our core areas. From its establishment in October 2007 up until 2019, the Gjensidige Foundation has distributed over NOK 2.7 billion to more than 8.500 projects that promote health and safety initiatives https://www.gjensidigestiftelsen.no/en/

About Hyde Park Investment

Hyde Park Investment was founded in 2004. We market investment funds to European institutional investors. Our firm has become one of the leading groups for distribution of traditional ESG and alternative funds to institutional investors; we offer truly pan-European coverage with offices in London, Madrid, Malta, and Paris. Archipelago Partners is Hyde Park's partner in the Nordics. https://hydeparkinvestment.com/

About Archipelago Partners

Archipelago Partners provides investors access to international asset managers by promoting select traditional and alternative managers' Funds and discretionary mandates into the Nordic countries. Archipelago Partners assists the investment managers with the marketing of their funds and managed accounts and help servicing their investors. http://www.archipelago-partners.com/

The material is for informational purposes only and should not be regarded as a recommendation or an offer to buy or sell any product or service to which this information may relate. Certain products and services may not be available to all entities or persons.

An investment in the fund involves risk; principal loss is possible. There is no guarantee the fund's investment objectives will be achieved. The value of equity and fixed income securities may decline significantly over short or extended periods of time. More information on these risk considerations, as well as information on other risks to which a fund is subject are included in the fund's prospectus.

Performance information provided is for the Rockefeller Asset Management – Climate Solutions Equity Composite as of 12/31/20, and may not be representative of current or future performance. The performance of individual accounts within a particular strategy will vary. Returns shown are based on daily, time-weighted total returns in US dollars that include unrealized and realized capital change and income earned from underlying holdings. Composite returns are calculated based in daily, asset-weighted individual portfolio returns using beginning-of-period values and net external asset movements. Trade date accounting is used for recording and valuing positions in the account. Dividends are recognized in the account on an ex-date basis. Performance results reflect the effect of cash and cash equivalents. Net of Fees performance returns shown reflect the gross performance after the deduction of an annual investment management fee of 1.20% deducted monthly - the highest breakpoint in effect under historical fee schedules during the periods shown. Rockefeller's standard management fees are disclosed in Part 2A of its Form ADV. Current performance may be lower or higher than the performance quoted. The returns of other portfolios included in the composite or for a new portfolio may vary from the information shown. Future results may vary substantially from past performance. No investment strategy can guarantee profit or protection from loss.

This release does not constitute or contain an offer, solicitation, recommendation or investment advice with respect to the purchase of the fund described herein or any security. Prospective investors should carefully consider fund objectives, risks, charges, tax considerations and expenses and other relevant information before investing. For this and more information on the Rockefeller Capital Management UCITS ICAV (the "ICAV"), please request a prospectus and read it carefully before you invest. Prospective investors should also consult their professional advisers as to the suitability of any investment in light of their particular circumstances and applicable citizenship, residence or domicile. The ICAV has been authorized in Ireland as a UCITS pursuant to the European Communities (Undertakings for Collective Investments in Transferable Securities) Regulations.

Shares of the fund are only available for certain non-U.S. persons in select transactions outside the United States, or, in limited circumstances, otherwise in transactions which are exempt from the registration requirements of the United States Securities Act of 1933, as amended and such other U.S. laws as may be applicable.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye